The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with ...
Interrupting signals exchanged between tumors and the nervous system could become a critical pillar of cancer care ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback